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Autoimmune beta cell destruction and pre type 1 diabetes mellitus {#sec2-1}
-----------------------------------------------------------------

Autoimmunity directed against pancreatic islet cells results in slowly progressing beta-cell destruction, culminating over years in clinically manifested insulin-dependent diabetes mellitus (IDDM). Circulating serum autoantibodies directed against the endocrine cells of the islets of Langerhans are an important hallmark of this disease.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39]\]

Before 1982, type 1 diabetes was diagnosed on the basis of clinical knowledge, with acute hyperglycemia and ketoacidosis being the major manifestations. Around 1982, the entity of pre-type 1 diabetes was discovered, which was asymptomatic and was the result of slowly progressive autoimmune beta cell destruction spread over 5--10 years or more.\[[@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref15][@ref16][@ref17][@ref19][@ref20][@ref22][@ref26][@ref27][@ref28][@ref29][@ref34][@ref37][@ref40]\]

Assays for islet cell autoantibodies (ICA) have facilitated the investigation and understanding of several facets in the pathogenesis of autoimmune diabetes \[[Figure 1](#F1){ref-type="fig"}\]. Their applications have extended into clinical practice and have opened new avenues for early preclinical prediction and preventive prophylaxis in IDDM/type 1 diabetes mellitus (T1DM).\[[@ref40]\]

![Immunofluorescence: Cytoplasmic islet cell autoantibodies](IJEM-19-58-g001){#F1}

Type 1 diabetes: Pathogenesis: Genetics-- environment-autoimmunity {#sec2-2}
------------------------------------------------------------------

A series of seminal discoveries in the 1980\'s, paved the way for the current model of type 1 diabetogenesis, consisting of sequential pathogenetic steps, beginning from birth: (1) Genetic predisposition; (2) initiation -- Triggering; (3) autoimmunity; (4) beta cell dysfunction -- destruction; and (5) clinical diabetes. This landmark model and concept are continuing to pave the way, for all subsequent global research efforts toward better understanding of the pathogenesis and possible prevention/cure of type 1 diabetes, till today.\[[@ref40]\]

Traditionally, it is considered that there is a genetic predisposition from birth, followed by initiation or triggering by unknown or partly known environmental factor(s), of a cascade of autoimmune responses, giving rise to progressive beta-cell dysfunction-destruction, which finally leads to clinical diabetes. This led to the first ever prospective pre type 1 diabetes mellitus (T1DM) registry at Joslin and kindled our and global scientific efforts towards finding an antigen-specific immunotherapy for the prevention of T1DM.

Another important, but less known, discovery at this period, shed additional novel insights for type 1 autoimmune diabetogenesis. Investigating the pathogenetic mechanisms for rapid failure of initially successful ("type 1 diabetes "cured") monozygotic twin to twin pancreas transplants (expected absence of rejection, thus obviating the need for post transplant immunosuppression), we also discovered the phenomenon of "recurrent or secondary autoimmune insulitis." This refers to the rapid reappearance of ICA post-transplant, and selective islet beta cell destruction in the grafted pancreas (never forgetting or "anamnestic" beta-cell destructive memory), in the absence of any graft pancreas rejection.\[[@ref12]\]

Insulitis {#sec2-3}
---------

In the early 1970\'s, the first demonstration of insulitis was made. Various stages of insulitis namely pre-insulitis, peri-insulitis, intra-insular insulitis and complete islet destruction have been demonstrated both in animal models and humans. Recently, surprisingly, differences in insulin content between T1DM islets, as well as, "patchy" or "lobular" destruction of islets have been described, (i.e., in few pancreas lobules all islets have preserved beta cells, while in other lobules, islets have no beta cells) -- reminiscent of autoimmune vitiligo and patchy skin lesions (? scientific basis of "patchiness" in a systemic autoimmune disease unexplained; also possible recovery and relapse, and simultaneous/parallel target cell destruction and regeneration). These unique pathobiological phenomena, suggest that beta cell destruction may not always be inexorable and inevitably complete/total, and thus raise hopes for possible therapeutic interruption of beta cell autoimmunity-- destruction and cure of type 1 diabetes \[[Figure 2](#F2){ref-type="fig"}\].\[[@ref41]\]

![Model of Type 1 diabetogenesis \[Genetically determined autoimmune beta cell destruction; pre-type 1 diabetes; primary and recurrent insulitis\]](IJEM-19-58-g002){#F2}

A very interesting recent study has indicated that MRI can be used to visualize inflammation in the pancreas that leads to type 1 diabetes. The researchers investigated the possibility of using MRI and ferumoxytol, a coated iron nanoparticle used as an iron replacement therapy, to image inflammation in the pancreas. Ferumoxytol leaks from blood vessels in areas of inflammation and is taken up by immune cells called macrophages, which accumulate at sites of inflammation. Ferumoxytol-MRI of the patient group showed clear evidence of ferumoxytol accumulation in the pancreas, indicating ongoing inflammation. MR images from the control group did not show the same accumulation. The MRI technique could help better define which patients will progress to diabetes and classify subgroups of patients who might benefit from different therapeutic strategies.\[[@ref42]\]

Islet cell autoantibodies {#sec2-4}
-------------------------

The corresponding islet cell autoantigens include, insulin antibodies (IAA), glutamic acid decarboxylase (GAD), tyrosine phosphatase-like protein (ICA 512 and IA-2) and zinc transporter 8 (ZnT8). Like in other autoimmune diseases, islet cell autoantigens are proving not to be only passive targets for beta cell destruction, but many \[? all\] of them seem to have significant physiological functions in the β-cells.

In a representative study, the prevalence of diabetes-associated autoantibodies in children with newly diagnosed type 1 diabetes was as follows: Islet cell cytoplasmic antibodies (ICA): 92.3%, glutamic acid decarboxylase antibodies (GADA): 67.0%, insulinoma-associated autoantibody (IA-2A): 76.0%, IAA: 44.8% and zinc transporter 8 A (ZnT8A): 62.7%. It was also found that 98% of newly diagnosed children had one or more antibodies, and 34% of children had nearly 4 antibodies.

Each antibody has different characteristics and possibly different pathophysiologic roles in type 1 diabetogenesis. The prevalence of all islet cell antibodies, except GAD, decreases with age in T1DM. Once the β cells are destroyed, the antibodies also subside. It is also found that younger the age, higher is the prevalence and titers of insulin antibodies, and faster is the β-cell destruction. However, this relation does not exist for GAD65 and ICA512 antibodies.

Persons with the A/A genotype for the insulin gene have higher IAA levels than people with A/T or T/T type. MHC haplotype sharing increases the risk of developing diabetes in DR3/4-DQ8 siblings, who also have higher percentage of autoantibodies. Risk is greater with those who share 2 MHC haplotypes, as opposed to those who share 1 or none. Beta cells for people with ICA + 0602 + DQ allele are apparently protected, and hence there is a lack of progression to diabetes in them.

Following the pioneering Joslin Prediabetes Registry Study of the 1980s,\[[@ref16]\] a number of natural history studies, including the Diabetes and Autoimmunity Study in the Young, Diabetes Prevention Trial Type-1, TrialNet, The Environmental Determinants of Diabetes in the Young, Prospective Assessment in Newborns for Diabetes Autoimmunity etc. have been conducted and data published on genetic, environmental and autoimmune determinants of type 1 diabetes.

Environment {#sec2-5}
-----------

The only definite environmental factor is congenital rubella, because of which children subsequently develop type 1 diabetes (an increased incidence of IDDM has been reported in patients with congenital rubella syndrome \[CRS\]. Diabetes can be classed among the delayed complications of CRS, but the overall incidence of insulin-requiring childhood-onset diabetes is more likely to have been in the range 1-3%, compared with higher values (20%) cited in the earlier literature\]. The putative predisposing factors are viruses (enteroviruses and rotaviruses) and components of infant diet including gluten and cow\'s milk. The putative protective factors are gut flora, helminths, viral infections, and sunlight (Vitamin D).

Prospective Finnish studies indicate that there is a temporal association between enteroviral infections and the first appearance of diabetes-associated antibodies. An antidiabetogenic vaccine is potentially feasible based on a few enterovirus serotypes.

The type 1 diabetes prediction and prevention study has shown that: (a) Infants start developing islet cell antibodies as early as 3 months after birth; and (b) seroconversion of enterovirus RNA in serum to autoantibody positivity is higher in T1DM cases than in controls.

Another study showed that IgG antibodies to bovine insulin are higher in those infants who were introduced to formula-feeds before 3 months of age than in those who were exclusively breast-fed for 3 months or more. Those infants with beta-cell autoimmunity had a rise in these antibodies to bovine insulin over the study period 18 months. The relative risk of developing T1DM in relation to: (a) Early (\<4 months of age) exposure to cow\'s milk was 1.6, and (b) short (\<3 months) duration of breastfeeding was 1.5.

Studies are in progress to evaluate the possibility to reduce the frequency of diabetes-associated autoantibodies by excluding dietary cow\'s milk proteins over the first 6--8 months of life in subjects at increased risk of T1DM. The TRIGR study showed that children, who were given casein hydrolysate up to 8 months, had decreased prevalence of ICA, compared with the control group. Further studies are underway where infants are given a highly hydrolyzed formula (casein hydrolysate) for 6 months, and observed whether this could be correlated with a delay in the development of antibodies and consequently delayed development of diabetes. A number of theories exist about the protective nature of the hydrolyzed formula against autoantibody production, including decreased gut permeability, maturation of regulatory T-cells in gut-associated lymphoid tissue, elimination of early exposure to intact bovine insulin, and effects on gut microbiota.

Vitamin D supplements have also been shown as an important factor in protecting T1DM development in early infancy.
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Next big idea??? hope and dream? {#sec2-6}
--------------------------------

This includes both type 1 diabetes "prevention" and "intervention" approaches.

Prevention of T1DM can include: Primary prevention strategies before the development of autoantibodies and secondary prevention regimens after autoantibody development. Once ICA has developed, the goal is to establish a therapeutic regimen to preserve at least 90% of the beta cells and prevent the development of hyperglycemia.

The targets for T1DM reversal should include autoimmunity, beta cell regeneration and protection of beta cell mass. Studies showed that delayed exposure to gluten did not delay development of T1DM. Neither parenteral insulin nor oral insulin delayed development of T1DM, overall. In the oral insulin trial, the children with baseline IAA ≥ 300 had delayed type 1 diabetes development for up to 10 years.

Numerous intervention immunotherapy trials have been conducted in new onset T1DM with the goal of preserving/increasing residual beta cell mass, and hopefully "switching off" of islet cell autoimmunity and beta cell destruction.

Immunotherapy intervention trials in new onset type 1 diabetes mellitus {#sec2-7}
-----------------------------------------------------------------------

MMF and DZB -- Peter Gottlieb, TrialNetHSP 65 p227 s.c. (Peptor) -- Jerry, Palmer, SeattleMulti-dose DZB -- Henry Rodriguez, IndianaExenatide and DZB -- David Harlan, NIHOral hIFN -- alpha -- Kristina Rother, NIHAnti-CD20 -- Mark Peskovitz, Indiana, TrialNetAnti-CD3 -- Protégé MacrogenicsMultidose anti-CD3 hOKT -- Kevan Herold, ITNRapamycin and IL-2, Greenbaum -- ITNCTLA4Ig -- Tihamer Orban, TrialNetglutamic acid decarboxylase 65 in Alum -- DiamydPro-insulin DNA Vaccine -- Bay HillATG (Sandostat) -- Steve Gitelman, UCSF, ITN, TrialNetGastrin and EGF-- Phase I TrialAlpha 1 anti-trypsin trials: Peter Gottlieb -- BDC and ITN.

Cyclosporine immunotherapy was associated with an increased remission rate in recently diagnosed T1DM (approach abandoned because of associated nephrotoxicity). Anti-CD3 teplizumab and anti-CD3 otelixizumab have been shown to provide C-peptide preservation. Potential of combination therapies are being explored (combination of immunotherapy, beta cell protection/regeneration therapies etc).

Future need and developments in the field will include: Assays for insulitis; better quantitation of beta cell mass, beta cell death or survival; and better assays for autoantibodies and for pathogenic T-cells. The unanswered questions in diabetes research include elimination of autoimmune memory responses, re-establishment of immune self-tolerance, and mechanisms of disease initiation.

Dr. S Srikanta: "Pranams" and salutations: Prof GS Eisenbarth: The most kind hearted and friendly human being, an aggressive scientific pioneer and my supervisor, for giving me the special and unique learning and serving opportunity, at the highest echelons of science and medicine in the world (Duke -- Joslin -- Harvard, USA: 1981--1987). Prof MMS Ahuja and Prof JS Soeldner: Two foremost mentors ("Gurus"), for initiating, inspiring, supporting and nurturing me (beginning 1978) during my life time scientific journey, with islet beta cells and children with type 1 diabetes. Stationed on the two sides of our planet, the foremost medical sage physician -- scientist -- teacher \[Prof MMS Ahuja\], and the greatest islet cell clinical physiologist-- investigator \[Prof. JS Soeldner\], laid the major early foundation for the entire work described in this article. The highest humility, honesty and hard work of these noble and caring souls \["unsung heros"\], and their contributions to Type 1 diabetes pathogenesis, prevention and care world over, must never be forgotten.

**Source of Support:** Nil

**Conflict of Interest:** None declared.
